Natera, Inc. (NASDAQ:NTRA) Shares Sold by Duquesne Family Office LLC

Duquesne Family Office LLC trimmed its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 4.6% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 3,402,330 shares of the medical research company's stock after selling 164,520 shares during the period. Natera comprises 15.7% of Duquesne Family Office LLC's investment portfolio, making the stock its biggest holding. Duquesne Family Office LLC owned approximately 2.52% of Natera worth $481,123,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Blue Trust Inc. increased its stake in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after buying an additional 97 shares during the period. Yousif Capital Management LLC purchased a new stake in Natera during the 4th quarter worth approximately $207,000. Choreo LLC increased its stake in Natera by 12.5% during the 4th quarter. Choreo LLC now owns 1,986 shares of the medical research company's stock worth $315,000 after buying an additional 220 shares during the period. Apollon Wealth Management LLC increased its stake in Natera by 10.5% during the 4th quarter. Apollon Wealth Management LLC now owns 2,345 shares of the medical research company's stock worth $371,000 after buying an additional 222 shares during the period. Finally, Savant Capital LLC increased its stake in Natera by 1.4% during the 4th quarter. Savant Capital LLC now owns 18,933 shares of the medical research company's stock worth $2,997,000 after buying an additional 259 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CFO Michael Burkes Brophy sold 2,562 shares of the company's stock in a transaction on Monday, March 31st. The shares were sold at an average price of $138.41, for a total value of $354,606.42. Following the completion of the sale, the chief financial officer now owns 75,557 shares in the company, valued at $10,457,844.37. This represents a 3.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gail Boxer Marcus sold 4,000 shares of the company's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $140.78, for a total transaction of $563,120.00. Following the completion of the sale, the director now owns 9,704 shares of the company's stock, valued at approximately $1,366,129.12. This trade represents a 29.19% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 68,275 shares of company stock worth $10,142,783. Corporate insiders own 7.60% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Canaccord Genuity Group reaffirmed a "buy" rating and set a $180.00 target price on shares of Natera in a research note on Wednesday, February 26th. Piper Sandler upped their target price on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Thursday, May 15th. BTIG Research reiterated a "buy" rating on shares of Natera in a report on Friday, February 28th. UBS Group boosted their price target on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Finally, Royal Bank of Canada assumed coverage on shares of Natera in a report on Thursday, March 13th. They set an "outperform" rating and a $251.00 price target for the company. One equities research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $184.63.

Natera Stock Up 0.6%

Shares of Natera stock traded up $0.99 during trading hours on Friday, hitting $165.34. The company had a trading volume of 729,330 shares, compared to its average volume of 1,410,918. The company's 50-day moving average is $154.56 and its two-hundred day moving average is $158.53. Natera, Inc. has a twelve month low of $92.14 and a twelve month high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The company has a market cap of $22.58 billion, a P/E ratio of -93.94 and a beta of 1.74.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.09. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $501.83 million during the quarter, compared to analysts' expectations of $446.68 million. During the same quarter in the prior year, the business posted ($0.56) EPS. The company's revenue for the quarter was up 36.5% on a year-over-year basis. Analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.